GleamWall
中文EN

IMRX Immuneering Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1790340 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.4%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.5%
ROA-31.4%
ROIC (approx.)-105.3%
Asset turnover—

Leverage & solvency

Liabilities / assets7.6%
Debt / equity0.00x
Current ratio13.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$20.72M$14.00M$10.65M$9.25M$10.87M$10.45M$11.47M$14.86M
SG&A expense$5.06M$5.00M$4.68M$4.49M$4.51M$4.30M$4.01M$3.69M
Operating income-$25.79M-$19.00M-$15.34M-$13.75M-$15.38M-$14.76M-$15.48M-$18.56M
Net income-$24.19M-$17.27M-$13.46M-$11.58M-$14.96M-$14.43M-$15.05M-$18.05M
EBITDA-$25.70M-$18.92M-$15.25M-$13.68M-$15.30M-$14.67M-$15.40M-$18.47M
EPS (basic)-0.37-0.27-0.21—-0.38-0.40-0.42—
EPS (diluted)-0.37-0.27-0.21—-0.38-0.40-0.42—
Weighted avg. shares (diluted)64.71M64.70M64.66M—39.67M35.99M35.53M—
Balance sheet
Cash & equivalents$58.23M$41.32M$47.32M$128.65M$227.56M$26.36M$35.87M$36.14M
Short-term investments——————$0$0
Current assets$150.71M$157.99M$161.41M$176.25M$229.10M$27.73M$38.21M$39.59M
PP&E, net$808,952$879,922$937,008$938,481$892,553$964,138$1.05M$1.12M
Goodwill$6.69M$6.69M$6.69M$6.69M$6.69M$6.69M$6.69M$6.69M
Intangibles$299,197$306,513$313,830$321,147$328,463$335,780$343,097$350,413
Total assets$182.56M$202.06M$214.81M$231.99M$241.06M$40.06M$50.68M$52.71M
Current liabilities$10.79M$8.12M$4.97M$10.07M$9.55M$7.49M$5.11M$7.50M
Total liabilities$13.88M$11.32M$8.29M$13.50M$13.08M$11.12M$8.84M$11.33M
Shareholders' equity$168.68M$190.74M$206.52M$218.48M$227.98M$28.94M$41.84M$41.39M
Cash flow statement
Operating cash flow-$16.79M-$16.50M-$18.43M-$9.84M-$11.98M-$9.45M-$14.08M-$14.51M
Capital expenditure$15,158$27,367$79,930$123,910$7,255$2,116$8,945$9,356
Free cash flow-$16.80M-$16.53M-$18.51M-$9.96M-$11.98M-$9.45M-$14.09M-$14.52M
Investing cash flow$33.47M$10.48M-$63.07M-$88.72M-$7,255-$2,116-$8,945$5.49M
Financing cash flow$220,174$24,608$180,760-$357,523$213.19M-$61,958$13.81M-$40,988
Depreciation & amortization$86,127$84,454$81,402$75,889$78,841$84,527$85,261$86,116
Stock-based compensation$2.06M$1.63M$1.64M$1.64M$1.46M$1.52M$1.69M$1.72M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.